So far, both, attenuating and aggravating effects of SLC expression on renal cystic diseases are poorly investigated, and addressing them will require elaborate animal models, for example ADPKD (autosomal dominant polycystic kidney disease) mouse models, treated with agonist or antagonist of individual SLCs. Here, CCL21 is linked to cystic kidney disease.